Abcellera Biologics Inc (ABCL)

$4.00 -0.01 (-0.25%)
Market Cap 1.22B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 3,719,570
Avg Vol 3,292,412
Day's Range N/A - N/A
Shares Out 303.16M
Stochastic %K 95%
Beta 0.85
Analysts Strong Sell
Price Target $9.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Nardwuar_
Nardwuar_ Apr. 20 at 6:38 PM
$ABCL I’m not in this but I just keep thinking back to the idea that Thiel still holds all his shares. He’s down like 80-90% too lol! Thiel probably realizes that this company just needed time to get everything right and organize before they have the chance of chucking patented treatments left and right worth billions. Only make sense long term. It was over a billion he invested, now worth 50 mil….
0 · Reply
GuslovesBio
GuslovesBio Apr. 20 at 5:22 PM
$ABCL Hot flash data: they wouldn't announce it this early if it wasn't positive...IMO..
1 · Reply
sogenerous
sogenerous Apr. 20 at 4:23 PM
$ABCL setting up nicely for high 4s low 5s later imo
2 · Reply
tradersunion353
tradersunion353 Apr. 20 at 4:07 PM
$ABCL 3 dollars forever adders and loaders will be like
0 · Reply
Rastafari
Rastafari Apr. 20 at 2:51 PM
$ABCL Good volume. Should end the day at around 4.5 million shares traded
0 · Reply
Smellmahass
Smellmahass Apr. 20 at 2:17 PM
$ABCL Small cap. Wont move much after data it seems.
0 · Reply
Rastafari
Rastafari Apr. 20 at 2:01 PM
$ABCL pre market vs Open, really odd move! Hope it’s just profit taking vs 635 data update that will be shared on earnings call!
3 · Reply
tkstockpicker
tkstockpicker Apr. 20 at 1:48 PM
$ABCL added
0 · Reply
tradersunion353
tradersunion353 Apr. 20 at 1:43 PM
$ABCL Overhyped underperforming JUNK. Should have been trading at minimum $6 mean while pumpers here so married for $3 range...
0 · Reply
DeMampCamp
DeMampCamp Apr. 20 at 1:26 PM
$ABCL Gap fill at the open and then let's rocket, baby!!
1 · Reply
Latest News on ABCL
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 20, 2026, 9:00 AM EDT - 5 hours ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 18 days ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 7 weeks ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 3 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 3 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 4 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 4 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 5 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 5 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 7 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 8 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

AbCellera Announces Resignation of Board Member

Feb 23, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Resignation of Board Member

Nardwuar_
Nardwuar_ Apr. 20 at 6:38 PM
$ABCL I’m not in this but I just keep thinking back to the idea that Thiel still holds all his shares. He’s down like 80-90% too lol! Thiel probably realizes that this company just needed time to get everything right and organize before they have the chance of chucking patented treatments left and right worth billions. Only make sense long term. It was over a billion he invested, now worth 50 mil….
0 · Reply
GuslovesBio
GuslovesBio Apr. 20 at 5:22 PM
$ABCL Hot flash data: they wouldn't announce it this early if it wasn't positive...IMO..
1 · Reply
sogenerous
sogenerous Apr. 20 at 4:23 PM
$ABCL setting up nicely for high 4s low 5s later imo
2 · Reply
tradersunion353
tradersunion353 Apr. 20 at 4:07 PM
$ABCL 3 dollars forever adders and loaders will be like
0 · Reply
Rastafari
Rastafari Apr. 20 at 2:51 PM
$ABCL Good volume. Should end the day at around 4.5 million shares traded
0 · Reply
Smellmahass
Smellmahass Apr. 20 at 2:17 PM
$ABCL Small cap. Wont move much after data it seems.
0 · Reply
Rastafari
Rastafari Apr. 20 at 2:01 PM
$ABCL pre market vs Open, really odd move! Hope it’s just profit taking vs 635 data update that will be shared on earnings call!
3 · Reply
tkstockpicker
tkstockpicker Apr. 20 at 1:48 PM
$ABCL added
0 · Reply
tradersunion353
tradersunion353 Apr. 20 at 1:43 PM
$ABCL Overhyped underperforming JUNK. Should have been trading at minimum $6 mean while pumpers here so married for $3 range...
0 · Reply
DeMampCamp
DeMampCamp Apr. 20 at 1:26 PM
$ABCL Gap fill at the open and then let's rocket, baby!!
1 · Reply
HelloWorld123456
HelloWorld123456 Apr. 20 at 1:19 PM
$ABCL
0 · Reply
Targhee
Targhee Apr. 20 at 12:15 PM
$ABCL 👀
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 20 at 3:03 AM
$ABCL Is up in Sunday night trading. https://x.com/JackPrescottX/status/2046005078885113921?s=20
2 · Reply
Rastafari
Rastafari Apr. 20 at 12:29 AM
$ABCL I know it’s Sunday night, but check out the pre market price!
0 · Reply
Art_BunyaaHa
Art_BunyaaHa Apr. 20 at 12:19 AM
$ABCL 🤜 🤛 420 and beyond 🚀
0 · Reply
EchoAnalysis8
EchoAnalysis8 Apr. 19 at 7:21 PM
$ABCL calm before the move 👀 Price is approaching the 200 DMA from below It’s simple — flip this level to support and it’s a buy Wave 5 target: +206% 🚀
0 · Reply
Kaykay610
Kaykay610 Apr. 19 at 2:29 PM
$ABCL https://x.com/i/status/2045381731927085537 Looks like things are moving behind the scenes. When this thing moves it will run
1 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 19 at 1:44 PM
$ABCL https://x.com/jinseongeo83473/status/2045774988553371783?s=20
0 · Reply
snowPOW
snowPOW Apr. 19 at 5:50 AM
$ABCL everything that I want to see, is essentially happening here. Great, slow growth, then poof* Millionaire maker here; CEO is focused, driven and smarter than me. Thanks for the "cheaps"
0 · Reply
chamono1942
chamono1942 Apr. 19 at 12:54 AM
$ABCL Let's go up to ten dollars!
0 · Reply
snowPOW
snowPOW Apr. 18 at 11:13 PM
$ABCL great week
0 · Reply
MorganHoratio
MorganHoratio Apr. 18 at 7:54 PM
20 Small Cap Stocks Across 20 Sectors — A 5-Year Framework（11-15） $SERV — Delivery Robotics $ZETA — AI powered marketing $EVER — Insurtech $PATH — Enterprise automation $ABCL — AI drug discovery All eyes are on $ZETA's upcoming earnings (April 30)—a critical litmus test for AI monetization. For $SERV, watch out for recent insider selling; while the narrative is strong, short-term profit-taking is a risk. Which of these "Pragmatic AI" sectors—Delivery, Marketing, or Automation—do you think will lead the pack in H2 2026? Drop your case in the comments!
1 · Reply